Jie Ying Wu

US Patent:

8324213, Dec 4, 2012

Filed:

Oct 6, 2009

Appl. No.:

13/122679

Inventors:

Kevin D. McCormick - Basking Ridge NJ, US
Li Dong - Lawrenceville NJ, US
Christopher W. Boyce - Flemington NJ, US
Manuel de Lera Ruiz - Branchburg NJ, US
Salem Fevrier - Cranford NJ, US
Jie Wu - Scotch Plains NJ, US
Junying Zheng - New Providence NJ, US
Jianhua Chao - San Diego CA, US
Walter S. Won - Alpine NJ, US
Ashwin U. Rao - Avenel NJ, US
Rongze Kuang - Green Brook NJ, US
Pauline C. Ting - New Providence NJ, US
Xianhai Huang - Warren NJ, US
Ning Shao - Clark NJ, US
Anandan Palani - Bridgewater NJ, US
Michael Y. Berlin - Flemington NJ, US
Robert G. Aslanian - Rockaway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/501
A61K 31/497
A61K 31/506
A61K 31/4439
A61K 31/427
A61K 31/423
C07D 235/02
C07D 405/02
C07D 409/02
C07D 413/02
C07D 263/52

US Classification:

51425206, 51425505, 514256, 514278, 514365, 514375, 544230, 546 15, 548147, 548216, 548247

Abstract:

In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.

US Patent:

20130303517, Nov 14, 2013

Filed:

Dec 19, 2011

Appl. No.:

13/996361

Inventors:

Christopher W. Boyce - Flemington NJ, US
Sylvia Joanna Degrado - Scotch Plains NJ, US
Xiao Chen - Edison NJ, US
Jun Qin - Edison NJ, US
Younong Yu - East Brunswick NJ, US
Kevin D. McCormick - Basking Ridge NJ, US
Anandan Palani - Bridgewater NJ, US
Dong Xiao - Warren NJ, US
Robert George Aslanian - Rockaway NJ, US
Jie Wu - Scotch Plains NJ, US
Ashwin Umesh Rao - Morganville NJ, US
Phieng Siliphaivanh - Newton MA, US
Joey L. Methot - Westwood MA, US
Hongjun Zhang - Newton MA, US
Elizabeth Helen Kelley - Lynnfield MA, US
William Colby Brown - Cleveland Heights OH, US
Qin Jiang - Latham NY, US
Jolicia Polivina Gauuan - Schenectady NY, US
Andrew J. Leyhane - Latham NY, US
Purakkattle Johny Biju - Piscataway NJ, US
Pawan K. Dhondi - Elizabeth NJ, US
Li Dong - Lawrenceville NJ, US
Salem Fevrier - Cranford NJ, US
Xianhai Huang - Warren NJ, US
Henry M. Vaccaro - South Plainfield NJ, US

International Classification:

C07D 241/42
C07D 401/12
C07D 403/06
C07D 471/04
A61K 31/4985
C07D 471/10
C07D 405/12
C07D 401/14
A61K 31/506
A61K 31/55
C07D 417/12
C07D 498/04
C07D 491/107
A61K 45/06
A61K 31/498

US Classification:

51421018, 544353, 514249, 544350, 544230, 51421021, 544295, 540523, 51421207

Abstract:

The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J, J, R, R, R, R, R, R, R, R, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction.

US Patent:

20180037554, Feb 8, 2018

Filed:

Feb 1, 2016

Appl. No.:

15/549242

Inventors:

- Rahway NJ, US
Rongze Kuang - Green Brook NJ, US
Yeon-Hee Lim - Piscataway NJ, US
Michael Man-Chu Lo - Bedminister, NJ
Pauline C. Ting - New Providence NJ, US
Purakkattle Biju - Piscataway NJ, US
Manuel de Lera Ruiz - Perkasie PA, US
Sylvia J. Degrado - Scotch Plains NJ, US
Alexander L. Tung - Bensalem PA, US
Timothy J. Henderson - Natick MA, US
Liwu Hong - East Brunswick NJ, US
Jae-Hun Kim - Scotch Plains NJ, US
Dong Won-Shik Kim - Rockville MD, US
Joe Lee - Rahway NJ, US
Jie Wu - Scotch Plains NJ, US
Heping Wu - Edison NJ, US
Yushi Xiao - Rahway NJ, US
Tao Yu - Edison NJ, US
Gang Zhou - Bridgewater NJ, US
Xiaohong Zhu - Edison NJ, US
Kevin D. McCormick - Basking Ridge NJ, US
Jayaram R. Tagat - Westfield NJ, US
Dong Xiao - Warren NJ, US
Tanweer Khan - Bridgewater NJ, US
Jianhua Cao - Edison NJ, US
Michael Berlin - Rahway NJ, US
Yonglian Zhang - Metuchen, NJ

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 239/84
C07D 401/14
C07D 413/12
C07D 417/12
C07D 405/12
C07D 417/14
C07D 413/14
C07D 471/04
C07D 401/12
C07D 403/12

Abstract:

The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist.